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ABSTRACT Downstream processes that discriminate between DNA adducts of a third generation platinum antitumor drug
oxaliplatin and conventional cisplatin are believed to be responsible for the differences in their biological effects. These different
biological effects are explained by the ability of oxaliplatin to form DNA adducts more efﬁcient in their biological effects. In this
work conformation, recognition by HMG domain protein and DNA polymerization across the major 1,2-GG intrastrand cross-link
formed by cisplatin and oxaliplatin in three sequence contexts were compared with the aid of biophysical and biochemical
methods. The following major differences in the properties of the cross-links of oxaliplatin and cisplatin were found: i), the
formation of the cross-link by oxaliplatin is more deleterious energetically in all three sequence contexts; ii), the cross-link of
oxaliplatin bends DNA slightly but systematically less in all sequence contexts tested; iii), the afﬁnity of HMG domain protein
to the cross-link of oxaliplatin is considerably lower independent of the sequence context; and iv), the Klenow fragment of DNA
polymerase I pauses considerably more at the cross-link of oxaliplatin in all sequence contexts tested. We have also
demonstrated that the chirality at the carrier ligand of oxaliplatin can affect its biological effects.
INTRODUCTION
Since the introduction of cisplatin [cis-diamminedichlorido-
platinum(II)] (Fig. 1 A), only [cis-diamminecyclobutanedi-
carboxylatoplatinum(II)] (carboplatin) and [(1R,2R-diamm-
inocyclohexane)oxalatoplatinum(II)] (oxaliplatin) (Fig. 1 A)
have received worldwide approval and achieved routine clin-
ical use (1). Carboplatin is less toxic than cisplatin and can be
given at a much higher dose than cisplatin. Unfortunately,
carboplatin is still only active in the same range of tumors as
cisplatin (2). As of yet, oxaliplatin, administered as a single
agent, has not demonstrated substantial advantages over cis-
platin or carboplatin although it has shown potential for use
in some cisplatin-resistant tumors if administered in combi-
nation with 5-ﬂuorouracil or folinic acid (3).
DNA is considered the major pharmacological target of
platinum compounds (4–6). Direct analogs of cisplatin,
which have already achieved routine clinical use, such as
carboplatin and oxaliplatin, produce on DNA adducts similar
to those produced by the parent drug, though different in
their relative rates of formation (6,7). Hence, from a mech-
anistic DNA-binding point of view, it is not too surprising
that the introduction of the new platinum antitumor drugs in
the clinic does not represent a fundamental breakthrough in
the treatment of cancer with platinum agents. This conclu-
sion is in accordance with the hypothesis systematically
tested by us and others that platinum agents, which bind to
DNA in a fundamentally different manner, may have altered
pharmacological properties (8–10). Nevertheless, the studies
on DNA interactions of cisplatin, carboplatin, and oxaliplatin
and their closely related analogs or models afforded a
number of interesting results that broaden theoretical back-
ground needed for the design of new, more effective,
platinum anticancer drugs.
For the reaction of oxaliplatin with DNA to occur, the par-
ent compound must become aquated. The hydrolysis of oxal-
iplatin to form reactive diaqua species [Pt(R,R-DACH)(H2O)2]
21
(DACH ¼ 1,2-diaminocyclohexane, Fig. 1 A) is a slower
process than the hydrolysis of cisplatin. Therefore, oxalipla-
tin is inherently less able than cisplatin to form DNA adducts
(11), but the sites in DNA of oxaliplatin adducts and their
spectrum are nearly identical to the situation when DNA is
modiﬁed by cisplatin (12). On the other hand, oxaliplatin
adducts are removed from DNA by a nucleotide excision
repair system (13) or by recombination repair (14) with
similar efﬁciency as cisplatin adducts. In contrast, DNA
adducts of oxaliplatin and cisplatin are processed by a mis-
match repair system (15) and translesion DNA polymerases
(16–18) differently. Despite lower DNA reactivity, oxalipla-
tin exhibits similar or greater cytotoxicity in several human
tumor cell lines. Thus, oxaliplatin requires fewer DNA lesions
than does cisplatin to achieve cell growth inhibition (11).
The overall conformational alterations induced in DNA by
the major 1,2-GG intrastrand cross-link (CL) of cisplatin and
the same adduct of oxaliplatin in the TGGT sequence were
studied by x-ray crystallography (19). The 1,2-GG intra-
strand CLs of cisplatin and oxaliplatin have been shown to
be similar although they differ in several details. The bulky
DACH ring of the oxaliplatin adduct ﬁlls much of the DNA
major groove, making it narrower and less polar at the site
of the CL. Recently, the solution structures of the 1,2-GG
intrastrand CL of oxaliplatin and cisplatin formed in the
AGGC sequence were solved (20,21), and again several
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conformational differences were observed between the
cisplatin-GG adduct and the oxaliplatin-GG adduct.
The structure of an oxaliplatin-GG adduct has been so far
described only for two sequence contexts, such as TGGT
and AGGC, although under different conditions. Besides
[Pt(R,R-DACH)]21 (oxaliplatin), another enantiomeric form
of this complex exists so that the biological activity of plat-
inum complexes with enantiomeric amine ligands such as
[PtX2(R,R-DACH)]
21 and [Pt X2(S,S-DACH)]
21 (Fig. 1 A)
are also of great interest. For instance, the DACH carrier
ligand has been shown to signiﬁcantly affect the ability of
platinum-DNA adducts to block essential processes such as
replication and transcription (22). Also, importantly, the
[PtCl2(S,S-DACH)]
21 complex, having an S conﬁguration at
the asymmetric carbon atoms, is markedly more mutagenic
toward several strains of Salmonella typhimurium than
[PtCl2(R,R-DACH)]
21 (23). Even more importantly, oxali-
platin (having l-gauche conformation of the diamine chelate
ring) exhibits higher activity toward various cancers than
the S,S-enantiomer (having d-gauche conformation) so that
oxaliplatin and not its S,S-enantiomer has been approved for
clinical use (24). Hence, although the asymmetry in the
amine ligand in these platinum complexes does not involve
the coordinated nitrogen atom but rather an adjacent carbon
atom, a dependence of the biological activity on the conﬁg-
uration of the amine is observed.
To allow drawing a more deﬁnite conclusion relating the
structural differences between the 1,2-GG intrastrand CLs of
oxaliplatin and cisplatin to the biological differences between
these two platinum drugs, we performed a more complex
study including the effect of the sequence context on the
structure of 1,2-GG intrastrand adduct of oxaliplatin using
gel electrophoretic retardation (phasing) assay, chemical
probes of DNA conformation, and differential scanning
calorimetry (DSC). We also performed studies aimed at
recognition of this adduct by HMG domain protein and the
inhibitory effect of this adduct on DNA polymerization in
vitro. The latter factors play an important role in the mech-
anism underlying antitumor effects of cisplatin (6,25). In
addition, we have also given several examples of how chi-
rality at the carbon atom of the carrier DACH ligand affects
some important factors that play a signiﬁcant role in the
mechanism of biological effects of cisplatin and its analogs.
MATERIALS AND METHODS
Chemicals
[Pt(R,R-DACH)(H2O)2](SO4) or [Pt(S,S-DACH)(H2O)2](SO4) (Fig. 1 A)
were prepared from the corresponding dichloro species (23) by treatment
with Ag2SO4 (26). Cisplatin was obtained from Sigma (Prague, Czech
Republic). The stock solutions of platinum compounds were prepared at a
concentration of 5 3 104 M in 10 mM NaClO4 and stored at 4C in the
dark. The synthetic oligodeoxyribonucleotides were synthesized and puri-
ﬁed as described previously (27). Expression and puriﬁcation of domain A
(residues 1–84) of the HMGB1 protein (HMGB1a) (HMG ¼ high-mobility
group) were carried out as described (28,29). T4 DNA ligase, the Klenow
fragment from DNA polymerase I (exonuclease minus, mutated to remove
the 39/59 proofreading domain) (KF), restriction endonuclease EcoRI,
and T4 polynucleotide kinase were purchased from New England Biolabs
(Beverly, MA). Deoxyribonucleoside 59-triphosphates were from Roche
Diagnostics (Mannheim, Germany). Acrylamide, bis(acrylamide), urea, and
NaCN were from Merck (Darmstadt, Germany). Dimethyl sulfate (DMS),
KMnO4, diethyl pyrocarbonate (DEPC), KBr, and KHSO5 were from
Sigma. Nonidet P-30 was from Fluka (Prague, Czech Republic). Radioactive
products were from Amersham (Arlington Heights, IL). Proteinase K and
ATP were from Boehringer (Mannheim, Germany).
Platinations of oligonucleotides
The duplexes containing single, central 1,2-GG intrastrand CL of [Pt(R,R-
DACH)]21, [Pt(S,S-DACH)]21, or cisplatin in the pyrimidine-rich top
strands were prepared as described (27). The platinated oligonucleotides
were puriﬁed by ion-exchange fast protein liquid chromatography (FPLC). It
was veriﬁed by platinum ﬂameless atomic absorption spectrophotometry
(FAAS) and by the measurements of the optical density that the modiﬁed
oligonucleotides contained one platinum atom. It was also veriﬁed using
DMS footprinting of platinum on DNA (30) that one DACH or cisplatin
molecule was coordinated to the N7 atom of the single G in the top strands of
each duplex. FPLC puriﬁcation and FAAS measurements were carried out
FIGURE 1 Structures of platinum compounds and sequences of the
synthetic oligodeoxyribonucleotides with their abbreviations. (A) Structures:
a, cisplatin; b, oxaliplatin; c, [Pt(R,R-DACH)]21; d, [Pt(S,S-DACH)]21. (B)
Sequences: the top and bottom strands of each pair in the ﬁgure are
designated ‘‘top’’ and ‘‘bottom’’, respectively, throughout. The boldface
letters in the top strands of the duplexes indicate the platinated residues.
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on a Pharmacia Biotech (Piscataway, NJ) FPLC System with MonoQ HR 5/
5 column and a Varian (Palo Alto, CA) AA240Z Zeeman atomic absorption
spectrometer equipped with a GTA 120 graphite tube atomizer, respectively.
The unmodiﬁed or platinated duplexes used in the studies of recognition by
HMGB1 domain proteins were still puriﬁed by electrophoresis on native
15% polyacrylamide (PAA) gel (mono/bis(acrylamide) ratio ¼ 29:1). Other
details have been described previously (27,31).
Ligation and electrophoresis of oligonucleotides
Unplatinated 20–23-mer single strands (bottom strands of the duplexes
described in the section DNA unwinding and bending) were 59-end-labeled
with [g-32P]ATP by using T4 polynucleotide kinase. Then they were
annealed with their phosphorylated complementary strands (unplatinated or
containing the platinum CL). The duplexes were allowed to react with T4
DNA ligase. The resulting samples along with ligated unplatinated duplexes
were subsequently examined on 8% native PAA (mono/bis(acrylamide)
ratio¼ 29:1) electrophoresis gels. Other details of these experiments were as
described in previous articles (32–34).
Chemical modiﬁcations
The modiﬁcation by KMnO4, DEPC, and KBr/KHSO5 were performed as
described previously (31,35–37). The strands of the duplexes were 59-end
labeled with [g-32P]ATP. In the case of the platinated oligonucleotides,
the platinum complex was removed after reaction of the DNAwith the probe
by incubation with 0.2 M NaCN (pH 11) at 45C for 10 h in the dark.
Gel mobility shift assay
The 59-end-labeled 22-bp oligonucleotide duplexes with blunt ends (their
sequences were identical to those of the duplexes TGGT (23), CGGA (23),
and AGGC (23) shown in Fig. 1 B except that they did not contain terminal
overhanging nucleotides) either unplatinated (controls) or containing the
central platinum adduct in their top strands were used, and their reaction with
HMGB1a protein was performed and analyzed as described previously (38).
Inhibition of DNA polymerization
We investigated in this work DNA polymerization using the templates site
speciﬁcally modiﬁed by [Pt(R,R-DACH)]21, [Pt(S,S-DACH)]21, or cis-
platin by KF. The DNA polymerase I class of enzymes has served as the
prototype for studies on structural and biochemical mechanisms of DNA
replication (39,40). In addition, as the most extensive genetic, biochemical,
and structural studies have been carried out on a Klenow fragment of DNA
polymerase I (including its exonuclease-deﬁcient analog), this enzyme
appears to be an ideal model system for investigating the molecular mech-
anisms associated with template-directed DNA synthesis (39,40).
The 23-mer templates (see Fig. 5 B, bottom) containing a single 1,2-GG
intrastrand adduct of [Pt(R,R-DACH)]21, [Pt(S,S-DACH)]21, or cisplatin
were prepared in the same way as described in the section Platinations of
oligonucleotides (vide supra); 8-mer DNA primer whose sequence is also
shown in Fig. 5 B was complementary to the 39 termini of the 23-mer
templates. The DNA substrates were formed by annealing templates and 59-
end-labeled primer (5 3 108 M) at a molar ratio of 3:1. All experiments
were performed at 25C in a volume of 50 ml in a buffer containing 50 mM
Tris-HCl (pH 7.4), 10 mM MgCl2, 0.1 mM dithiothreitol, 50 mg/ml bovine
serum albumin, 100 mM deoxyadenosine 59-triphosphate, 100 mM deox-
ycytidine 59-triphosphate, 100 mM deoxyguanosine 59-triphosphate, and
100 mM thymidine 59-triphosphate and 0.5 unit of KF. Reactions were
terminated by the addition of EDTA so that its resulting concentration was 20
mM and by heating at 100C for 30 s. Products were resolved by denaturing
20% PAA/8 M urea gel and then visualized and quantiﬁed by using the
FUJIFILM bioimaging analyzer and AIDA image analyzer software.
Differential scanning calorimetry
Excess heat capacity (DCp) versus temperature proﬁles for the thermally
induced transitions of TGGT (15), CGGA (15), and AGGC (15) duplexes
(see Fig. 1 B for their sequences) unmodiﬁed or containing a unique 1,2-GG
intrastrand CL of cisplatin, [Pt(R,R-DACH)]21, or [Pt(S,S-DACH)]21 were
measured using a VP-DSC calorimeter (Microcal, Northampton, MA). In
the DSC experiments the concentrations of the duplexes were 30 mM, the
heating rate was 60C/h, and the maximum temperature was 95C. After
reaching the maximum temperature the samples were cooled at the same rate
to the starting temperature of 25C. In this study DCp is deﬁned as excess
heat capacity, which is baseline subtracted and concentration normalized
(41). The reference scans were subtracted from the sample scans to obtain
DCp versus temperature proﬁles. Enthalpies (DHcal) and entropies (DS) of
duplex melting were calculated from the areas under the experimental DCp
versus T and derived DCp/T versus T curves, respectively, using ORIGIN
v.5.0 software (Microcal, Studio City, CA). The free energy of duplex dis-
sociation at 25C (DG25) was calculated using the standard thermodynamic
relationship given in Eq. 1 and the corresponding DH and DS values:
DG
0
25 ¼ DH  ð298:15ÞDS: (1)
The duplexes were dissolved in the buffer containing 10 mM sodium
phosphate (NaH2PO4/Na2HPO4) pH 7.0 and 150 mM NaCl. It was also
veriﬁed in the same way as described in previous articles (42,43) that the
melting transitions of both the platinated and unmodiﬁed duplexes were
fully reversible.
RESULTS
Conformational changes produced in double
helical DNA by the site-speciﬁc 1,2-GG
intrastrand cross-link
The goal of our work was to establish whether the steric
structure of the nonleaving group of platinum DACH enan-
tiomers could inﬂuence the distortions induced in DNA by
the formation of the 1,2-GG intrastrand CL. We directed our
studies on establishing distortions and other biophysical
properties of oligodeoxyribonucleotide duplexes containing
a single, site-speciﬁc 1,2-GG intrastrand CL of [Pt(R,R-
DACH)]21 or [Pt(S,S-DACH)]21 in three central sequences,
such as TGGT, AGGC, and CGGA.
Differential scanning calorimetry
A calorimetric technique was used to characterize the inﬂu-
ence of the 1,2-GG intrastrand CL of [Pt(R,R-DACH)]21 or
[Pt(S,S-DACH)]21 on the thermal stability and energetics of
the site speciﬁcally platinated 15-mer DNA duplexes. Such
thermodynamic data can reveal how the platinum adduct
inﬂuences duplex stability, a property that has been shown to
play a signiﬁcant role in the mechanism of antitumor activity
of platinum drugs (42,44,45). Recently, calorimetric and
spectroscopic techniques were used to characterize the inﬂu-
ence of the 1,2-GG intrastrand CL on the thermal stability
and energetics of a 20-mer DNA duplex site speciﬁcally
modiﬁed by cisplatin, antitumor dinuclear platinum com-
plex, and [Pt(R,R-DAB)]21 or [Pt(S,S-DAB)]21 (DAB ¼
2,3-diaminobutane) (42,46,47). We expanded these studies
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on the oligodeoxyribonucleotide duplex containing unique
1,2-GG site-speciﬁc intrastrand adducts of the [Pt(R,R-
DACH)]21 or [Pt(S,S-DACH)]21 complexes.
Fig. 2 shows DSC melting proﬁles (DCp versus T) for the
parent, nonmodiﬁed 15-bp duplexes TGGT (15), AGGC
(15), and CGGA (15) (solid curves) and the same duplexes
containing single 1,2-GG intrastrand CL of cisplatin (dot and
dashed curves), [Pt(R,R-DACH)]21 (dashed curves), or
[Pt(S,S-DACH)]21 (dotted curves). Each transition shows
negligible changes in the heat capacities between the initial
and ﬁnal states, and denaturation (heating) and renaturation
(cooling) curves for the unmodiﬁed and platinated duplexes
were superimposable (not shown), which is consistent with
the reversibility of the melting equilibrium. The interpre-
tation of our calorimetric data described below is also based
on the assumption that all thermodynamic parameters for
melting of the unmodiﬁed and platinated duplexes are as-
cribed to differences in the initial duplex states. This implies
that the ﬁnal single-stranded states should be thermodynam-
ically equivalent at the elevated temperatures at which they
are formed. This assumption has been veriﬁed similarly as in
earlier reports by recording identical circular dichroic spectra
for the samples of nonplatinated and platinated duplexes that
were heated to high temperatures (42–44,46,48). In aggre-
gate, meaningful thermodynamic data from our calorimetric
measurements described below could be obtained.
DSC melting proﬁles were analyzed as described in
Materials and Methods to obtain the results listed in Table 1.
All thermodynamic parameters discussed in this work refer
to the duplex dissociation process. Differences in the disso-
ciation thermodynamics due to the presence of the adduct
are presented as ‘‘DD’’ parameters. These parameters are
computed by subtracting the appropriate value measured for
control, unmodiﬁed duplex from the value measured for the
duplex containing the single, site-speciﬁc platinum adduct
and are reported in Table 1 in parentheses.
Inspection of these thermodynamic parameters reveals
a number of interesting features: First, CL formation of
[Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21 reduced the du-
plex thermal stability. The CLs of both enatiomers reduced
DNA melting temperature to the same extent that they would
if they were formed in the sequences AGGC or CGGA; and
this reduction was slightly greater than that induced by the
CL of cisplatin formed in the same sequences. Interestingly,
CL formation of cisplatin and DACH complexes reduced the
duplex thermal stability more extensively if these CLs were
formed in the TGGT sequence than in the other two se-
quences. In addition, whereas the CL of [Pt(R,R-DACH)]21
reduced DNA melting temperature to the same extent as
cisplatin, the CL of [Pt(S,S-DACH)]21 was in this respect
more efﬁcient. Second, CL formation by cisplatin and
DACH complexes resulted in a large decrease of the en-
thalpy of duplex dissociation (Table 1). In other words, the
intrastrand CL of these platinum complexes enthalpically
destabilizes the duplex relative to their nonmodiﬁed coun-
terpart. Third, CL formation by [Pt(R,R-DACH)]21, [Pt(S,S-
DACH)]21, or cisplatin resulted in a substantial decrease in
duplex dissociation entropy (Table 1). In other words, the
intrastrand CL of both DACH enantiomers and cisplatin
increases the entropy of the duplex. Fourth, the net result of
these enthalpic and entropic effects is that 1,2-GG intrastrand
CL formation by [Pt(R,R-DACH)]21, [Pt(S,S-DACH)]21, or
cisplatin in TGGT, CGGA, or AGGC sequences induces a
decrease in the free energy for duplex dissociation at 25C
(DG25) (Table 1), this duplex destabilization being enthalpic
in origin. In this respect, the intrastrand CLs of DACH
complexes were more effective than that of cisplatin if the
FIGURE 2 DSC thermograms for the (A) TGGT (15), (B) CGGA (15),
and (C) AGGC duplexes unmodiﬁed (solid lines) and containing in the
top strand 1,2-GG intrastrand adduct of cisplatin (dot and dashed line),
[Pt(R,R-DACH)]21 (dashed line), and [Pt(S,S-DACH)]21 (dotted line). The
concentrations of the duplexes were 30 mM, and the buffer conditions were
10 mM sodium phosphate pH 7.0 and 150 mM NaCl.
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CLs were formed in the CGGA or AGGC sequences. On the
other hand, if the CLs of [Pt(R,R-DACH)]21 and cisplatin
were formed in the TGGT sequence, the difference in the
ability of these CLs to thermodynamically destabilize the
duplex was notably small. Interestingly, the intrastrand CL
of [Pt(S,S-DACH)]21 formed in this latter sequence ther-
modynamically destabilized the duplex considerably more
than its R,R counterpart.
DNA unwinding and bending
Among the alterations of secondary and tertiary structure of
DNA to which it may be subjected, the role of intrinsic
bending and unwinding of DNA is increasingly recognized
as being potentially important in regulating replication and
transcription functions through speciﬁc DNA-protein inter-
actions. For cisplatin adducts, the structural details respon-
sible for bending and subsequent protein recognition have
recently been elucidated (49,50). Given the recent advances
in our understanding of the structural basis for the bending
of DNA caused by cisplatin, it is of considerable interest to
examine how the character of a carrier amine in the 1,2-GG
intrastrand adduct affects conformational properties of DNA,
such as bending and unwinding. In this work we further per-
formed studies on the bending and unwinding induced by
single, site-speciﬁc intrastrand CLs of [Pt(DACH)]21 enanti-
omers formed in oligodeoxyribonucleotide duplexes between
neighboring guanine residues in three sequence contexts.
As in the previous study (47), we used electrophoretic
retardation as a quantitative measure of the extent of planar
curvature to analyze bending and unwinding induced by
the single, site-speciﬁc 1,2-GG intrastrand CL formed by
[Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21 in the sequences
TGGT, CGGA, and AGGC. The oligodeoxyribonucleotide
duplexes TGGT (20–23), CGGA (20–23), and AGGC (20–
23), used for DNA bending and unwinding studies, were
20–23-bp long and had sequences identical or similar to
those of the duplexes TGGT (21), CGGA (21), or AGGC
(21) (Fig. 1 B), respectively; the 20-bp duplexes had one
terminal CG pair deleted, whereas one additional TA pair
was added to the 39 end in the 22-bp duplex and TA and CG
pairs were added to the 39 end in the 23-bp duplex). The liga-
tion products of these unplatinated or [Pt(DACH)]-containing
duplexes were analyzed on native PAA electrophoresis gel.
Experimental details of these studies are given in our recent
report (47). A representative gel and its analysis showing
the mobility of the ligation products of 20–23-bp duplexes
containing single, site-speciﬁc 1,2-GG intrastrand CL of
[Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21 at the central se-
quence TGGT in a PAA gel is demonstrated in the Supple-
mentary Material (Fig. S1). The results are summarized in
Table 2. The DNA bending toward the major groove in the
range of 29–33 and unwinding in the range of 18–22 due
to the single, site-speciﬁc 1,2-GG intrastrand CL formed by
[Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21 were similar for
both enantiomers if the CLs were formed in the CGGA or
AGGC sequences. The direction of the bend was determined
using the 33-bp duplexes, which also contained, besides the
single 1,2-GG intrastrand CL formed by either Pt-DACH
enantiomer, the (A-T)5 tract located ‘‘in phase’’ from the CL
(the cross-linked basepair and the center of the A tract were
separated by 11 bp), in the same way as in our recent articles
(51–53). Somewhat different results were obtained for the
CLs in the TGGT sequence. The bending toward the major
groove due to the single, site-speciﬁc 1,2-GG intrastrand CL
formed by [Pt(R,R-DACH)]21 was markedly greater than
TABLE 1 Calorimetrically derived thermodynamic parameters for dissociation (melting) of the 15-bp duplexes unmodiﬁed or
containing a single, site-speciﬁc 1,2-GG intrastrand CL of cisplatin, [Pt(R,R-DACH)]21, or [Pt(S,S-DACH)]21
TGGT(15) Tm (C) DH (kcal/mol) DS (cal/mol) DG025 ðkcal=molÞ
no Pt (control) 58.9 96.8 294.1 9.1
cisplatin 48.7 63.0 (33.8) 196.7 (97.4) 4.4 (4.7)
[Pt(R,R-DACH)]21 48.1 59.9 (36.9) 187.3 (106.8) 4.1 (5.0)
[Pt(S,S-DACH)]21 45.3 56.7 (40.1) 178.4 (115.7) 3.5 (5.6)
CGGA(15) Tm (C) DH (kcal/mol) DS (cal/mol) DG025 ðkcal=molÞ
no Pt (control) 64.5 102.1 305.2 11.1
cisplatin 57.5 67.8 (34.3) 206.8 (98.4) 6.1 (5.0)
[Pt(R,R-DACH)]21 55.0 61.4 (40.7) 188.0 (117.2) 5.3 (5.8)
[Pt(S,S-DACH)]21 54.9 64.4 (37.7) 197.8 (107.4) 5.4 (5.7)
AGGC(15) Tm (C) DH (kcal/mol) DS (cal/mol) DG025 ðkcal=molÞ
no Pt (control) 62.1 99.8 300.2 10.3
cisplatin 55.8 84.2 (15.6) 257.7 (42.5) 7.4 (2.9)
[Pt(R,R-DACH)]21 53.9 72.2 (27.6) 221.9 (78.3) 6.0 (4.3)
[Pt(S,S-DACH)]21 53.9 73.6 (26.2) 226.6 (73.6) 6.0 (4.3)
The DH and DS values are averages derived from three independent experiments. The experimental uncertainties of the parameters are as follows: Tm
(60.5C), DHcal (62%), DS (63%), DG025 (63%). ‘‘DD’’ parameters are in parentheses (these parameters are computed by subtracting the appropriate value
measured for control, unmodiﬁed duplex from the value measured for the duplex containing the single, site-speciﬁc platinum adduct).
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that induced by [Pt(S,S-DACH)]21, and similarly the un-
winding angle due to the CL of [Pt(R,R-DACH)]21 was
greater than that due to the CL of [Pt(S,S-DACH)]21.
Chemical probing of conformational distortions
To further characterize the distortion induced in DNA by in-
trastrand CLs of [Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21,
the 23-bp duplexes TGGT (23), CGGA (23), or AGGC (23)
containing the 1,2-GG intrastrand CL of either enantiomer
were treated with several chemical agents that are used as
tools for monitoring the existence of conformations other
than canonical B-DNA. These agents included KMnO4,
bromine, or DEPC as probes for thymine, cytosine, and
adenine/guanine residues, respectively (31,35–37,54). These
chemical probes react, under the conditions used, with base
residues in single-stranded DNA and distorted double-
stranded DNA, but not with the base residues in intact,
double-stranded DNA (31,35–37,54).
For this analysis, we used exactly the same methodology
as in our recent studies dealing with DNA adducts of various
antitumor platinum drugs. Thus, the details of this experi-
ment can be found in those articles (31,55), and a representa-
tive gel showing piperidine-induced speciﬁc strand cleavage
at KMnO4-modiﬁed, KBr/KHSO5-modiﬁed, and DEPC-
modiﬁed bases in the 23-bp TGGT duplex unplatinated or
containing single 1,2-GG intrastrand CL of [Pt(R,R-DACH)]21
or [Pt(S,S-DACH)]21 is demonstrated in the Supplementary
Material (Fig. S2). The results are schematically summarized
in Fig. 3. The pattern and degree of reactivity toward the
chemical probes were identical for the CLs formed by both
enantiomers in the sequences CGGA or AGGC, indicating
a similar character of the conformational distortion. This is
in contrast to the results of the analogous experiments carried
out with the duplex containing the CLs in the sequence
TGGT, where the pattern and degree of reactivity toward the
chemical probes was different for the CLs of the two
enantiomers (Fig. 3), indicating a chirality-dependent char-
acter of the conformational distortion.
Recognition by domain A of HMGB1 protein
An important feature of the mechanism of action of cisplatin
is that the major adducts of this platinum drug, the 1,2-GG
intrastrand CLs, are recognized by proteins containing HMG
domains (6,25,56). Importantly, DNA modiﬁed by trans-
platin or monodentate platinum(II) compounds, such as
[PtCl(dien)]1 (dien ¼ N-(2-aminoethyl)ethane-1,2-diamine)
or [PtCl(NH3)3]
1, is not recognized by these cellular
proteins (57). It has been shown (25,50) that the binding of
these proteins to DNA treated with cisplatin may mediate
the antitumor effects of this platinum drug. In addition, it has
been shown (58,59) that the replacement of one or both
ammine groups in cisplatin by various, mostly cyclic, non-
leaving ligands altered the afﬁnity of HMG box proteins for
the 1,2-GG intrastrand CLs. Hence, it was of great interest to
examine whether the replacement of the ammine ligands of
cisplatin by the chiral DACH ligand could also affect the
afﬁnity of HMG box proteins for this adduct.
HMGB1 is an abundant chromosomal protein which
binds preferentially without sequence speciﬁcity to bent or
distorted DNA structures including CLs formed by cisplatin.
HMGB1 consists of two tandem HMG box domains (A
and B, HMGB1a and HMGB1b, respectively) which share
a common HMG box structure. It has been shown that
HMGB1a has a markedly higher binding afﬁnity for dis-
torted DNA including 1,2-GG intrastrand CLs. Thus, the
full-length HMGB1 protein binds to the 1,2-GG intrastrand
CL of cisplatin primarily through domain A (60). As it is
mainly domain A that is essential for binding to the spe-
ciﬁc structure produced by the 1,2-GG intrastrand CL of
cisplatin, the interactions of this domain (HMGB1a) with the
1,2-GG intrastrand CLs of [Pt(R,R-DACH)]21 or [Pt(S,S-
DACH)]21 were investigated using gel mobility shift assay.
In these experiments, the 22-bp duplexes containing the
central sequence TGGT, CGGA, or AGGC (these 22-bp
oligonucleotide duplexes had blunt ends and their sequences
were identical to those of the duplexes TGGT (23), CGGA
(23), and AGGC (23) shown in Fig. 1 B except that they
did not contain terminal overhanging nucleotides) were
modiﬁed so that they contained a single, site-speciﬁc 1,2-GG
TABLE 2 DNA bending and unwinding induced by the 1,2-GG
intrastrand CL of cisplatin, [Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21
within the TGGT, CGGA, and AGGC contexts, as determined
by the gel electrophoresis retardation assay
cisplatin* [Pt(R,R-DACH)]21 [Pt(S,S-DACH)]21
TGGT
bendingy 34 31 23
unwinding 20 19 16
CGGA
bendingy 34 30 30
unwinding 19 18 18
AGGC
bendingy 33 28 34
unwinding 20 20 22
*Data from Stehlikova et al. (64).
yToward major groove.
FIGURE 3 Summary of the reactivity of chemical probes with the duplexes
TGGT, CGGA, and AGGC containing 1,2-GG intrastrand CL of cisplatin,
[Pt(R,R-DACH)]21, or [Pt(S,S-DACH)]21. Solid, half-solid and open circles
designate strong, medium, or weak reactivity, respectively.
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intrastrand CL of cisplatin, [Pt(R,R-DACH)]21, or [Pt(S,S-
DACH)]21.
The binding of the HMGB1a to these DNA probes was
detected by retardation of the migration of the radiolabeled
22-bp probes through the gel (Fig. 4). HMGB1a exhibited
negligible binding to the unmodiﬁed 22-bp duplexes. As
indicated by the presence of a shifted band whose intensity
increases with increasing protein concentration, HMGB1a
recognizes the duplexes TGGT, CGGA, or AGGC containing
the 1,2-GG intrastrand CL of [Pt(R,R-DACH)]21, [Pt(S,S-
DACH)]21, or cisplatin (shown for HMGB1a and CLs
formed by [Pt(R,R-DACH)]21, [Pt(S,S-DACH)]21, or cis-
platin in the TGGT sequence in Fig. 4 A). Interestingly,
HMGB1a binds the probes containing the 1,2-GG intrastrand
CL in the CGGA and AGGC of either enantiomer with an
afﬁnity which is very similar for both sequences and for both
enantiomers and approximately half as much as that of cis-
platin (Fig. 4 B). In contrast to this observation was the
afﬁnity of HMGB1a protein to the 1,2-GG intrastrand CLs
of [Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21 formed in the
22-bp duplex containing a central TGGT sequence in the top
strand. Whereas the protein binds to the CL of [Pt(R,R-
DACH)]21 and cisplatin with comparable afﬁnities and these
are, on the average, greater than those observed for the CLs
formed in the CGGA or AGGC sequences, a very weak
binding is observed for the 1,2-GG intrastrand CL formed by
[Pt(S,S-DACH)]21, which is even lower than those observed
for the CL formed by this complex in the CGGA and AGGC
sequences (Fig. 4 B).
In aggregate, the afﬁnity of HMGB1a protein to the
1,2-GG intrastrand CLs of either [Pt(DACH)]21 enantiomer
was considerably lower than that to the same CL of cisplatin
(Fig. 4 B) except the CL formed in the TGGT sequence; the
afﬁnity of HMGB1a to the CL of cisplatin and [Pt(R,R-
DACH)]21 were very similar and relatively high, whereas
that to the CL of [Pt(S,S-DACH)]21 was particularly low.
DNA polymerization by Klenow fragment
of DNA polymerase I
To learn more about the molecular basis of the replication of
DNA modiﬁed by oxaliplatin, we investigated in this work
DNA polymerization using the DNA templates site specif-
ically modiﬁed with 1,2-GG intrastrand CLs of [Pt(R,R-
DACH)]21 or [Pt(S,S-DACH)]21 in the TGGT, CGGA, or
AGGC sequences.
The DNA polymerization was examined by the Klenow
fragment of DNA polymerase I (61). The exonuclease-
deﬁcient Klenow fragment (KF) was selected here because
translesion synthesis (TLS) proﬁcient DNA polymerases of
the X or Y families share some common properties including
lack of associated 39–59 exonuclease proofreading activity,
and, not least, the proofreading mechanism itself may intro-
duce effects more dependent on the adduct type (62).
To assess the translesion replication capacity of KF we
investigated its capacity to elongate a 59 32P-labeled 8-mer
primer annealed to untreated 23-mer templates or to 23-mer
templates containing the 1,2-GG intrastrand CL of [Pt(R,R-
DACH)]21, [Pt(S,S-DACH)]21, or cisplatin formed in the
TGGT, CGGA, or AGGC sequences depicted in Fig. 5 B.
The 39 guanine involved in the 1,2-GG intrastrand CL on the
template strand was located at its 13th position from the 39
terminus (positioning the 39-end of the primer ﬁve bases
before the ﬁrst platinated base in the template strand) (Fig. 5
B). The newly synthesized DNA products were resolved
by denaturing PAA gel electrophoresis and visualized by
radiography.
DNA polymerization through the single 1,2-GG intra-
strand CL of [Pt(R,R-DACH)]21, [Pt(S,S-DACH)]21, or
cisplatin formed in the TGGT, CGGA, or AGGC sequences
of the templates by KF in the presence of all four deoxy-
ribonucleoside 59-triphosphates was stopped at various time
intervals, and the products were resolved by a sequencing gel
(shown in Fig. 5 A for the CLs formed by [Pt(R,R-DACH)]21
or [Pt(S,S-DACH)]21 in the TGGT sequence). Polymeriza-
tion proceeded rapidly up to the nucleotide opposite that
preceding the 1,2-intrastrand CLs, such that the 12-, 13-, and
14-mer products accumulated to a signiﬁcant extent. KF
efﬁciently replicated the untreated template; no intermediate
products were seen with the 23-mer control templates as the
full-length products were formed (Fig. 5 A). There was no
accumulation of other shorter or larger DNA intermediates.
Signiﬁcant amounts of the full-length products were also
noticed with the 23-mer templates containing the CLs of
FIGURE 4 The differential binding of HMGB1a to the 22-bp duplexes with
central TGGT, CGGA, or AGGC sequences (in the top strand) containing the
single, site-speciﬁc 1,2-GG intrastrand CL of cisplatin, [Pt(R,R-DACH)]21, or
[Pt(S,S-DACH)]21; the concentration of the duplex was 10 nM and the
concentration of HMGB1a was in the range of 2–30 nM. (A) Representative
gel showing binding of HMGB1a to the duplex with central TGGT sequence.
(B) Bar graph illustrating Q values (protein-bound duplex/total duplex ratio).
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[Pt(R,R-DACH)]21, [Pt(S,S-DACH)]21, or cisplatin formed in
the TGGT, CGGA, and AGGC sequences at longer times of
incubation of the templates with KF (60 min), although in a
markedly smaller amount than with the nonmodiﬁed tem-
plate; the amount of the full-length products accumulated
with the template containing the CL of cisplatin was always
greater than those accumulated with the templates containing
the CL of [Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21 in all
sequence contexts tested (Fig. 5 C). Importantly, the amount
of the full-length products noticed with the 23-mer template
containing the CLs of [Pt(R,R-DACH)]21, [Pt(S,S-DACH)]21,
or cisplatin formed in the CGGA or AGGC sequences was
pronouncedly smaller than that observed for the templates
containing the CLs in the TGGT sequence (Fig. 5 C).
DISCUSSION
This complex study was performed to help clarify a more
deﬁnite correlation between the structural differences of
1,2-GG intrastrand CLs of oxaliplatin and cisplatin and
differences in biological effects of these two platinum drugs.
We focused in thiswork on the effects of ﬂanking sequences on
DNAconformation at the site of the adduct and in its proximity.
In addition, since DNA is a chiral molecule, it may interact in a
different way with the platinum complexes containing enan-
tiomeric amine ligands, such as [Pt(R,R-DACH)]21 (oxalipla-
tin) or [Pt(S,S-DACH)]21. Hence, we also paid attention to
understanding how the chirality at the carbon atoms of the
carrier ligand in [Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21
can affect properties of the 1,2-GG intrastrand CL, which is
the major DNA lesion of conventional cisplatin and most
likely relevant to its antitumor effects.
DNA is considered a major pharmacological target of
platinum anticancer drugs (4,25). Hence, a possible expla-
nation for the different biological activity of oxaliplatin
([Pt(R,R-DACH)]21) and cisplatin on one hand and [Pt(R,R-
DACH)]21 and [Pt(S,S-DACH)]21 enantiomers on the other
hand can be associated with the different conformational
distortions induced in DNA by the adducts of these com-
pounds and their different processing in the cell. To test this
hypothesis the experiments described in this work were
carried out.
The presence of the 1,2-GG intrastrand adduct of cisplatin,
[Pt(R,R-DACH)]21 (oxaliplatin), and [Pt(S,S-DACH)]21
reduces the thermal stability of the duplexes TGGT (15),
CGGA (15), or AGGC (15). However, the thermal melting
is not a thermodynamic parameter. DSC can also provide
quantitative, model-independent characterizations of effects
of the lesion on duplex thermodynamics. Introduction of the
1,2-GG intrastrand adduct of cisplatin, [Pt(R,R-DACH)]21,
and [Pt(S,S-DACH)]21 decreases the DG25 for dissociation
of all duplexes. Interestingly, the DG25 values observed for
melting of the CGGA (15) and AGGC (15) duplexes
containing CL of [Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21
were identical (5.3/5.4 or 6.0 kcal/mol, respectively, Table
1), suggesting that the conformational alterations induced by
the CLs formed by both enantiomers in either CGGA or
AGGC sequences were similar. On the other hand, the above
FIGURE 5 Primer extension activity of
KF using the 8-mer/23-mer, primer/
template duplex. (A) The experiments were
conducted for the times indicated in the
ﬁgure (3–60 min) using undamaged tem-
plate (lanes 1–5), the template containing
single, site-speciﬁc 1,2-GG intrastrand CL in
the TGGT sequence of [Pt(R,R-DACH)]21
(lanes 6–10) or [Pt(S,S-DACH)]21 (lanes
11–15). The pause sites opposite the plati-
nated guanines and a ﬂanking residue on the
39 site are marked 14, 13, and 12, respec-
tively. (B) The nucleotide sequences of the
templates containing central TGGT, CGGA,
or AGGC sequences and the primer. See the
text for details. (C) The time dependence of
the inhibition of DNA synthesis on undam-
aged (control) templates (solid squares),
DNA-containing 1,2-GG intrastrand CL of
[Pt(R,R-DACH)]21 (solid circles), [Pt(S,S-
DACH)]21 (open circles), or cisplatin
(squares) in the TGGT (top), AGGC (mid-
dle), or CGGA (bottom) sequence. Data are
means from three different experiments with
two independent template preparations.
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mentioned DG25 values observed for melting of the duplexes
CGGA (15) and AGGC (15) containing CL of [Pt(R,R-
DACH)]21 or [Pt(S,S-DACH)]21 were considerably lower
than those observed for the same duplexes containing the CL
of cisplatin (6.1 or 7.4 kcal/mol, respectively). These differ-
ences in free energy represent an equilibrium preference for
the CGGA (15) duplex modiﬁed by the CL of cisplatin over
that modiﬁed by the CL of [Pt(R,R-DACH)]21 or [Pt(S,S-
DACH)]21 of ;4 to 1 (;11 to 1 for the platinated AGGC
(15) duplex).
Different results were, however, obtained for melting the
duplexes containing the CL in the sequence TGGT. TheDG25
values observed for melting the TGGT (15) duplex contain-
ing the CL of [Pt(R,R-DACH)]21 or cisplatin were similar
(4.1 or 4.4 kcal/mol, Table 1). This result implies similar
conformational alterations induced by the 1,2-GG intrastrand
CLs of cisplatin and oxaliplatin formed in the TGGT se-
quence in contrast to the case when the CLs of these drugs
were formed in CGGA and AGGC sequences (vide supra).
Another striking difference between the 1,2-GG intrastrand
CLs formed in CGGA or AGGC sequences on one hand and a
TGGT sequence on the other hand consists of the different
effects of theCLsof [Pt(R,R-DACH)]21 and [Pt(S,S-DACH)]21
enantiomers, the latter being more effective in destabilizing
double-helical DNA, but only if it was formed in the TGGT
sequence (DG25 of 3.5 kcal/mol, Table 1).
Inspection of Table 1 shows that the melting of each
duplex is accompanied by unfavorable free energy terms
which result from characteristic compensation of unfavor-
able enthalpy and favorable entropy terms. In general, the
unfavorable (endothermic) enthalpy results primarily from
the endothermic heats for disrupting basepairs and base-base
stacks of the duplex, whereas the favorable entropy terms
arise from contributions of the favorable dissociation into
two separate strands. Relative to the duplexes containing the
1,2-GG intrastrand CL of cisplatin, those containing the CL
of oxaliplatin f[Pt(R,R-DACH)]21g are higher in enthalpy
for all sequences tested, mostly if the CL was formed in the
AGGC sequence, whereas the least perturbation was observed
for the CL formed in the TGGT sequence. Hence, the for-
mation of the 1,2-GG intrastrand adduct by oxaliplatin is more
deleterious energetically than the formation of the same adduct
by cisplatin. This observation may be explained in terms of a
higher decrease in stacking interactions due to the CL of
oxaliplatin than due to that of cisplatin although the extent of
this decrease appears to be dependent on the sequence context.
The changes in free energy of the duplexes (TGGT,
CGGA, and AGGC), DG25, as a consequence of the forma-
tion of the single, site-speciﬁc intrastrand CL of cisplatin,
[Pt(R,R-DACH)]21, and [Pt(S,S-DACH)]21 between gua-
nine residues in the top strands (DDG25), reﬂect a combi-
nation of enthalpic (DDH) and entropic (DDS) effects (see
the values in parentheses in Table 1). The magnitudes of
these effects vary with the platinum complex and sequence
context. The observed DDG25 values are signiﬁcantly
smaller than the observed DDH values (the values of DDH
range from 40.7 to 15.6 kcal/mol, whereas the values of
DDG25 range from only 5.8 to 2.9 kcal/mol). This result
is the consequence of a considerable, but not complete,
compensation of the change in DDS. Interestingly, the higher
DDH is accompanied by the higher DDS.
Structural features of DNA, such as local bending and
unwinding at the site of the 1,2-GG intrastrand CLs of cis-
platin, play a very important role in the mechanism of
antitumor effects of this metallodrug (63). Interestingly, local
bending and unwinding due to the 1,2-GG intrastrand CL
of cisplatin are very little affected by the bases ﬂanking the
CL (64). On the other hand, the bending and unwinding
angles due to the 1,2-GG intrastrand CLs of the chiral
analogs ([Pt(DACH)]21) as well as the closely related
[Pt(DAB)]21 (DAB ¼ 2,3-diaminobutane) are dependent on
the sequence context (65). For instance, the character of
distortions determined by chemical probes and phasing assay
due to the single, site-speciﬁc 1,2-GG intrastrand CL formed
by the chiral analog of cisplatin [Pt(DAB)]21 in the CGGA
sequence were identical for both enantiomers; in contrast,
these properties of the 1,2-GG CLs formed in the sequence
context of TGGT by [Pt(DAB)]21 depend pronouncedly on
the chirality of the diamine (47). It has been shown (65) that
the latter structural and chiral differentiation of DNA adducts
of [Pt(DAB)]21 originates from clashes of the 59-oriented
methyl group of the DAB ligand with the methyl group of
the 59-thymine of the TGGT sequence. This explanation was
fully consistent with the observation that this chiral differ-
entiation disappeared if the 59 thymine was replaced by
cytosine such as in the sequence CGGA (65). The strict
analogy between DACH and DAB complexes suggests that
the dependence of distortion, including DNA bending and
unwinding angles due to the 1,2-GG intrastrand CLs of
[Pt(DACH)]21 on sequence context and on [Pt(DACH)]21
chirality, can be explained in a similar way. Hence, the
structural differentiation also observed for [Pt(DACH)]21
enantiomers is likely to originate from clashes of the 59-
oriented methylene group of [Pt(S,S-DACH)]21 with the
methyl group of the 59-thymine in the TGGT sequence. On
the other hand, owing to the absence of such clashes in the
CGGA sequence no effect of chirality of DACH compounds
on the bending and unwinding angles is observed (Table 2).
We also examined conformational alterations induced in
DNA by the 1,2-GG intrastrand CL of [Pt(R,R-DACH)]21 or
[Pt(S,S-DACH)]21 formed in a third sequence, AGGC. The
overall character of these structural distortions induced in
DNA by the CL of [Pt(R,R-DACH)]21 is very similar to that
observed for this enantiomer or cisplatin in both TGGT and
CGGA sequences. The only difference between the 1,2-GG
intrastrand CLs of [Pt(R,R-DACH)]21 and cisplatin consists
of a smaller bending angle (by 3–4) found for the CL of
oxaliplatin in all sequence contexts tested in this work. It is
possible that the bulky DACH group located in the major
groove restricts to some degree the DNA bending toward
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the major groove required for the formation of the 1,2-
intrastrand CL. In aggregate, we have found no distinctly
pronounced dependence of the structural properties of 1,2-
GG intrastrand CLs of [Pt(R,R-DACH)]21 (oxaliplatin),
such as local DNA bending and unwinding on the sequence
context, as it was also observed earlier in our laboratory for
the same CLs of cisplatin (64).
On the other hand, these structural features of 1,2-GG
intrastrand CLs of [Pt(DACH)]21 formed at an AGGC se-
quence are chirality dependent, but apparently differently
than in the TGGT sequence. Thus, DNA bending and un-
winding due to the 1,2-GG intrastrand CL of [Pt(S,S-DACH)]21
are considerably more dependent on sequence context than
the same adducts of cisplatin or oxaliplatin. Further struc-
tural studies are needed to explain this observation.
An important feature of the mechanism of action of
cisplatin is that the 1,2-intrastrand CLs formed by this drug
are speciﬁcally recognized by various proteins, including
those containing HMG domains (6,25,56). We have found
(47) that the recognition by domains of HMGB1 protein of
the 1,2-GG intrastrand CLs formed in the sequence context
of TGGT by the chiral [Pt(DAB)]21 (which is closely related
to [Pt(DACH)]21) depends on the chirality of the asymmet-
ric centers (66). We have also found (65) that this structural
differentiation originates from clashes of the 59-oriented
methyl group of the DAB ligand with the methyl group of
the 59-thymine and that this chiral differentiation disappears
in sequences XGG, with X being different from T. On the
other hand, the domains of HMGB1 proteins have been
shown to bind to the GG CL of [Pt(R,R-DAB)]21 and
[Pt(S,S-DAB)]21within the CGGA sequence with the same
afﬁnity (65). We have demonstrated in this and earlier (65)
work that the recognition by HMGB1a, which dominates the
interaction between HMGB1 and platinum-damaged DNA
(58), of the 1,2-GG intrastrand CLs formed in the sequence
context of TGGT and CGGA by the chiral [Pt(DACH)]21
depends on the chirality of the asymmetric centers in a way
very similar to that of [Pt(DAB)]21, i.e., only if the CL is
formed in the TGGT sequence different binding of HMGB1a
protein to the CLs of the two enantiomers is observed. In
addition, nomarked differences in the recognition by HMGB1a
of the 1,2-GG intrastrand CLs formed in the sequence context
of AGGC was observed (Fig. 4).
As shown for the 1,2-GG intrastrand CL of cisplatin (49),
HMGB1a binds to DNA around the site of this adduct in the
minor groove whereas the ammine ligands coordinated to
platinum reside in the major groove. It is therefore unlikely
that the afﬁnity of HMGB1a to the 1,2-GG intrastrand CLs
of [Pt(R,R-DACH)]21 and [Pt(S,S-DACH)]21 is affected in a
dominant way by direct interactions of the enantiomeric
nonleaving ligands with the protein. The very important
structural elements that contribute to recognition of cisplatin
adducts by cellular proteins are bending toward major
groove and unwinding of the DNA helix (56). However, no
apparent correlation exists between the binding afﬁnity of
HMGB1a to the 1,2-GG intrastrand CL formed by [Pt(R,R-
DACH)]21 or [Pt(S,S-DACH)]21 in various sequence con-
texts and the bend or unwinding angles induced by these
adducts (Table 2). This result may be interpreted to mean that
DNA prebending toward the major groove due to the 1,2-GG
intrastrand CL of [Pt(R,R-DACH)]21 or [Pt(S,S-DACH)]21
plays an important role in its recognition by HMG domain
proteins, but other factors contribute to the stability of the
complex formed between platinated DNA and these proteins.
DNA adducts of antitumor platinum drugs, such as cis-
platin, are believed to exert their cytotoxic effects by in-
hibiting both replication and/or transcription and inducing
programmed cell death (apoptosis) or necrosis (67). On the
other hand, in vitro bypass by replicative DNA polymerases
of helix-distorting DNA lesions, including DNA adducts
of some platinum compounds, has been observed as well
(68–71). Several DNA polymerases have been shown to by-
pass 1,2-GG intrastrand CLs of oxaliplatin with different efﬁ-
ciency than cisplatin-CLs (17,72), which has been proposed
to contribute to the different biological effects of these drugs.
We have demonstrated in this work that DNA polymerase
KF paused at the site of the 1,2-GG intrastrand CL formed
by [Pt(DACH)]21 enantiomers in all sequence contexts tested
in this work considerably more than at the CL of cisplatin
(Fig. 5). This result is consistent with a higher TLS observed
past cisplatin adducts compared to that past oxaliplatin ad-
ducts observed in several tumor cell lines (73,74). It is
possible that bulkier DACH lesions can interfere with the
conformational change of the polymerase to the closed cat-
alytically active ternary complex (DNA-polymerase-dNTP)
more than cisplatin lesions. Presumably, these bulky adducts
may alter the structure and stability of the ternary complex,
thus affecting an important step that is crucial in determining
the rate of the nucleotide incorporation step.
The TLS past 1,2-GG intrastrand CL of [Pt(DACH)]21,
which was considerably smaller than that past the CL of cis-
platin, was also chirality dependent (Fig. 5). More pronounced
differences were observed mainly if the CLwas formed in the
TGGT sequence (Fig. 5C) where TLS past the CL of [Pt(R,R-
DACH)]21 was markedly more extensive than that past the
CLof [Pt(S,S-DACH)]21.Much information is available regard-
ing the TLS efﬁciencies of various lesions and polymerases,
but a number of important details of the structural features of
the DNA polymerase-DNA substrate interaction that are re-
quired to accomplish TLS have yet to be revealed. The inability
of a polymerase to carry out DNA synthesis past DNA damage
may reﬂect the polymerase’s inability to position a lesion-
containing basepair in a geometric conformation that allows
active site assembly and catalysis. Thus, inhibition of synthesis
may also be due to the inability of the polymerase to extend
the 39 lesion-containing terminus. Interestingly, the pattern
and degree of reactivity toward the chemical probes were
different, but only for the CLs of the two enantiomers formed
in the TGGT sequence (Fig. 3). This observation indicates a
chirality-dependent character of the conformational distortion
DNA Intrastrand Cross-Link of Oxaliplatin 3959
Biophysical Journal 93(11) 3950–3962
in this sequence, which correlates with a chirality-dependent
TLS past the [Pt(DACH)]21-CL (Fig. 5) only observed in this
sequence context. The striking feature of the structure of the
1,2-GG intrastrand CL of [Pt(DACH)]21 enantiomers
revealed by chemical probes is that distortions induced by
these CLs are different mainly on the 39 side of the lesion, the
distortion being more extensive on this side of the CL for the
[Pt(R,R-DACH)]21 enantiomer. Thus, our data support the
idea that an important factor facilitating TLS byKF past 1,2-
GG intrastrand CL of cisplatin and its direct analogs is an
extensive distortion on the 39 side of this lesion.
CONCLUSIONS
DNA is considered a major pharmacological target of
antitumor effects of platinum drugs. Downstream processes
that discriminate between DNA adducts of oxaliplatin and
cisplatin are believed to be responsible for the differences in
biological effects of these two metallodrugs used clinically,
such as antitumor activity and mutagenicity. In addition,
different biological effects of oxaliplatin in comparison with
cisplatin are often explained by the ability of oxaliplatin to
form fewer DNA adducts, but due to their different structural
properties these adducts are more effective for biological
effects. The major DNA adduct of cisplatin is an intrastrand
CL formed between neighboring purine bases so that con-
siderable attention has been paid to differences between
properties of this adduct formed by cisplatin and oxaliplatin.
Some structural differences have already been demonstrated
(19,20), but a deﬁnite conclusion about factors involved in
the mechanism underlying different cytotoxic and mutagenic
response to these metallodrugs cannot yet be drawn. In this
work we focused on comparison of conformation, recogni-
tion by HMG domain protein, and DNA polymerization
across 1,2-GG intrastrand CL formed by cisplatin and oxali-
platin in three sequence contexts with the aid of biophysical
and biochemical methods. We found the following:
1. The formation of the 1,2-GG intrastrand adduct by
oxaliplatin is more deleterious energetically than the
formation of the same adduct by cisplatin in all three
sequence contexts. The calorimetric data suggest that
oxaliplatin CLs exhibit a higher efﬁciency to reduce
stacking interactions in DNA than the CLs of cisplatin,
although the extent of this reduction appears to be de-
pendent on the sequence context.
2. The 1,2-GG intrastrand CLs of oxaliplatin f[Pt(R,R-
DACH)]21 enantiomerg bends DNA slightly, but sys-
tematically less than the CL of cisplatin (by 3–4) in all
sequence contexts tested in this work. It is suggested that
the bulky DACH group located in the major groove
restricts in some degree the DNA bending toward the
major groove required for the formation of the 1,2-
intrastrand CL. On the other hand, the structural prop-
erties of 1,2-GG intrastrand CLs of (oxaliplatin), such as
local DNA bending and unwinding, are almost indepen-
dent of the sequence context as observed earlier in our
laboratory for the same CLs of cisplatin (64).
3. The afﬁnity ofHMGdomain protein (HMGB1a) to the 1,2-
GG intrastrand CLs of oxaliplatin is considerably lower than
that to the same CL of cisplatin independent of the se-
quence context. It is suggested that the bulkyDACHgroup
in the 1,2-GG intrastrand CL restricts to some extent the
additional DNA bending required for the protein binding.
4. DNA polymerase KF, which serves as the prototype for
studies on structural and biochemical mechanisms of
DNA replication, pauses at the site of the 1,2-GG in-
trastrand CL of oxaliplatin in all sequence contexts tested
in this work considerably more than at the CL of cis-
platin. It is suggested that bulkier DACH lesions can in-
terfere with the conformational change of the polymerase
to the closed catalytically active ternary complex (DNA-
polymerase-dNTP) more than cisplatin lesions.
We hypothesize that if not all, at least some of the differ-
ences between properties of the 1,2-GG intrastrand CL of
cisplatin and oxaliplatin and its processing observed in this
work could be involved in the different biological effects of
these two metallodrugs. However, cisplatin and its antitumor
analogs also form other types of adducts on DNA. The
relative efﬁcacy of DNA adducts in antitumor effects of
these metallodrugs has not been univocally determined.
Thus, it cannot be excluded that there are still distinct dif-
ferences in the properties of other adducts of cisplatin and
oxaliplatin and in their cellular processing. Revelation of
these differences will complement theoretical background
needed to explain differences in biological effects of these
clinically used metallodrugs and could also help in the
design of new platinum drugs.
In addition, we have also demonstrated examples of how
the chirality at the carrier DACH ligand can affect some
important factors that play a signiﬁcant role in the mechanism
of biological effects of cisplatin and its analogs. Interestingly,
we notice speciﬁc properties of the 1,2-GG intrastrand CLs
formed by [Pt(DACH)]21 complexes in the TGGT sequence,
which may give rise to speciﬁc, hitherto undisclosed biolog-
ical effects of these lesions. The information contained in this
work can be useful for better understanding how the stereo-
chemistry of the carrier amine ligands of cisplatin analogs can
modulate their anticancer and mutagenic properties.
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